US 12,435,059 B2
AMP-activated protein kinase inhibitors and methods of making and using the same
Philip Reigan, Denver, CO (US); Christopher J. Matheson, Newcastle upon Tyne (GB); and Craig Jordan, Aurora, CO (US)
Assigned to The Regents of the University of Colorado, A Body Corporate, Denver, CO (US)
Appl. No. 17/620,317
Filed by The Regents of the University of Colorado, Denver, CO (US)
PCT Filed Jul. 2, 2020, PCT No. PCT/US2020/040611
§ 371(c)(1), (2) Date Dec. 17, 2021,
PCT Pub. No. WO2021/003339, PCT Pub. Date Jan. 7, 2021.
Claims priority of provisional application 62/870,672, filed on Jul. 3, 2019.
Prior Publication US 2022/0289707 A1, Sep. 15, 2022
Int. Cl. C07D 401/06 (2006.01); A61P 35/02 (2006.01)
CPC C07D 401/06 (2013.01) [A61P 35/02 (2018.01)] 19 Claims
OG exemplary drawing
 
1. A compound of Formula (I):

OG Complex Work Unit Chemistry
a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein:
A is pyrrole;
RN is H;
R1 is N-(2-(diethylamino)ethyl);
R2 is CH3;
R3 is CH3;
R4 is H;
R5 is 5-(2-cyanoethyl).